Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Brain Neoplasms 276Glioblastoma 250Glioma 156Astrocytoma 99Central Nervous System Neoplasms 70Gliosarcoma 69Oligodendroglioma 63Neuroblastoma 63Neoplasms 52Breast Neoplasms 44Melanoma 42Carcinoma, Non-Small-Cell Lung 38Neoplasm Metastasis 33Medulloblastoma 30Lymphoma 29Recurrence 28Lung Neoplasms 27Ependymoma 24Sarcoma 20Ovarian Neoplasms 19Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Meningioma 18Lymphoma, Non-Hodgkin 18Leukemia 18Meningeal Carcinomatosis 17Burkitt Lymphoma 17Multiple Myeloma 16Lymphoma, Large B-Cell, Diffuse 16Diffuse Intrinsic Pontine Glioma 15

Interventions

4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hemangioblastoma × CNS × Clear all
NCT01266070 2017-02-13

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled 5 charts
CNS

von Hippel-Lindau Disease, Central Nervous System Neoplasms, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡